We have previously shown that in tumor specimens from patients with diffuse large B-cell lymphoma, not otherwise specified (DLBCL, NOS), the tumor necrosis factor-a (TNF-a)positive type correlates with a poorer prognosis compared with the TNF-a-negative type. In the present study, we further evaluated 60 lymphoma tissue specimens from patients with DLBCL, NOS by immunohistochemical staining with antibodies against TNF-a receptor 1 (TNFR1) and TNF-a receptor 2 (TNFR2). Our results demonstrated that 31 cases (52%) were positive and 29 (48%) were negative for TNFR1 and that the TNFR1-positive cases were significantly correlated with a poorer overall survival (OS; P = 0.0006, log rank test) than the TNFR1-negative cases. The TNFR2-positive cases tended to have a poorer OS than the TNFR2-negative cases, although the difference was not significant. TNFR1 expression in tumor cells was a significant prognostic factor for OS and was independent of the International Prognostic Index (IPI). Among 31 TNF-apositive DLBCL, NOS cases, 27 (87%) were positive and 4 (13%) were negative for TNFR1. Both TNF-a-positive and TNFR1-positive cases were significantly correlated with a poorer OS compared with the TNF-a-positive but TNFR1negative cases. Twenty-seven cases (45%) with the TNF-apositive and TNFR1-positive subtype of DLBCL, NOS had a poorer prognosis for OS and progression-free survival compared with the 33 cases (55%) with the remaining subtypes, and the TNF-a-positive and TNFR1-positive subtype of DLBCL, NOS was also shown to be independent of the IPI. In addition to the IPI, the prognosis of patients can be more accurately identified by evaluating both TNF-a and TNFR1 expression.
D iffuse large B-cell lymphoma (DLBCL) is a neoplasm that comprises large B-lymphoid cells with a diffuse growth pattern, and it accounts for 30% to 40% of non-Hodgkin lymphomas. 1, 2 Some variants have been distinguished from DLBCL, including: T-cell/histiocyte-rich large B-cell lymphoma; primary DLBCL of the central nervous system; primary cutaneous DLBCL, leg type; and Epstein-Barr virus (EBV)-positive DLBCL of the elderly. 3 However, many DLBCL cases remain clinically and/or morphologically heterogenous and are designated as DLBCL, not otherwise specified (NOS). 3 Despite the use of anthracycline-based chemotherapy, durable remission is achieved in only 40% to 50% of patients with DLBCL, NOS. 2 Therefore, it is important to identify the subtype of patients who may benefit from more aggressive or novel experimental therapies. Currently, the prognosis of patients with DLBCL, NOS is estimated according to the clinical parameters of the International Prognostic Index (IPI). 4 However, the IPI appears insufficient for the prognosis of patients and does not adequately reflect the underlying biological differences in each case. Till date, factors such as bcl-2 expression, Ki-67 index, or CD44 expression in tumor cells have been evaluated to better determine the different clinical outcomes in patients, leading to more accurate prognostic values and facilitating the provision of appropriate therapeutic strategies. 5 We previously reported the patients who were positive for tumor necrosis factor-a (TNF-a; gene symbol, TNF) correlated with a poorer overall survival (OS) and progression-free survival (PFS) than the TNF-a-negative patients, and TNF-a expression in tumor cells proved to be a significant prognostic factor, independent of the IPI. 6 TNF-a mediates its effects through 2 different receptors, TNF-a receptor 1 (TNFR1) (also known as TNFRSF1A, CD120a, or p55) and TNFR2 (also known as TNFRSF1B, CD120b, or p75). 7 All known responses to TNF-a are triggered by binding to either of these 2 distinct receptors, which are differentially regulated on various cells of normal and diseased tissues. 8 Therefore, in the present study, we immunohistochemically examined the expression of these receptors in DLBCL, NOS cells and investigated the relationship between the expression of these receptors and the prognosis of the patients.
MATERIALS AND METHODS

Case Samples
We examined 60 previously untreated patients with DLBCL, NOS (36 male and 24 female; mean age ± SD, 66 ± 14 y) who were diagnosed and treated between 2002 and 2013. Of these patients, 40 were previously reported 6 and available for immunohistochemical analysis of TNFR1 and TNFR2, and 20 were newly added. All patients were initially treated with an R-CHOP regimen that comprised rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone. 9 Diagnosis of DLBCL, NOS was based on the World Health Organization classification system, 3 and the disease extent was categorized according to the Ann Arbor classification system. 10 The IPI system was used to divide the patients into the following groups: low risk (L, IPI score = 0 to 1); low-intermediate risk (LI, IPI score = 2); high-intermediate risk (HI, IPI score = 3); and high risk (H, IPI score = 4 to 5). 4 No patient was infected with human immunodeficiency virus or human T-cell lymphotropic virus-I.
Histopathology and Immunohistochemical Staining
All tumor tissues, obtained from each patient by lymph node biopsy, were fixed in 10% buffered formalin, embedded in paraffin, cut to a thickness of 4 mm, and stained with hematoxylin and eosin and periodic acid-Schiff. Immunohistochemical staining was performed using primary antibodies against the following: CD3 (PS1; Nichirei, Tokyo, Japan), CD5 (4C7; Nichirei), CD10 (56C6; Dako, Glostrup, Denmark), CD20 (SL26; Kyowa Medex, Tokyo, Japan), BCL6 (LN22; Novocastra, Newcastle, UK), MUM1 (MUM1p; Dako), TNF-a (52B83; Santa Cruz Biotechnology, Santa Cruz, CA), TNFR1 (H-271; Santa Cruz Biotechnology), and TNFR2 (Enzo Life Sciences, Farmingdale, NY). Negative control slides were processed without applying the primary antibodies against TNF-a, TNFR1, or TNFR2 but included all other steps of the procedure. A case was considered positive if Z30% of the tumor cells stained positive for CD10, BCL6, and MUM1 according to the method reported by Hans et al. 11 For immunophenotypical subdivisions, any DLBCL, NOS sample that was positive for CD10 or BCL6 and negative for MUM1 was considered to have a germinal center-like (GCB) phenotype, whereas other DLBCL, NOS samples were regarded to have a non-germinal center-like (non-GCB) phenotype. 11 For CD5, membranous reactivity in Z20% of the tumor cells was considered positive according to the method reported by Yamaguchi et al. 12 For TNF-a, TNFR1, and TNFR2, reactivity in Z20% of the tumor cells was considered positive, as described previously. 6 In situ hybridization was performed on paraffin-embedded sections using the INFORM EBV-encoded RNA assay (Ventana Medical Systems Inc., Tucson, AZ) according to the manufacturer's instructions and an automated slide stainer system (Bench-Mark XT; Ventana). A known EBV-infected lymphoid tissue section served as a positive control in each run.
Statistical Analysis
Associations between TNFR1 or TNFR 2 expression and the clinical variables were determined using the t test and w 2 test. OS was calculated as the time between the onset of treatment and death or the date of the last follow-up evaluation. PFS was calculated from the onset of treatment until relapse, disease progression, death, or the last follow-up evaluation. OS and PFS were estimated according to the Kaplan-Meier method, and statistical comparisons were made using the log rank test. Univariate analyses were used to assess the values of the prognostic factors for the prediction of OS and PFS, and multivariate analyses were applied to test the novel prognostic factors' independence of the IPI, which has been established as a prognostic factor, using the Cox proportional hazards regression model and the likelihood ratio test. P values <0.05 were considered significant. Statistical analyses were performed using JMP Pro 10 (SAS Institute Inc., Cary, NC).
RESULTS
Clinical Characteristics of Patients
The clinicopathologic features of the patients at presentation are summarized in Table 1 . Of the 60 patients with DLBCL, NOS, 38 (63%) patients were alive and 22 (37%) patients died during the follow-up period. Of the 22 patients who died, the cause of death was primarily progression of lymphoma in 19 (86%) patients, pneumonia in 2 (9%) patients, and colon cancer in 1 (5%) patient.
Histologic Features and Immunohistochemical Results
Histologic examinations of the hematoxylin and eosin-stained lymph node biopsy specimens showed diffuse proliferation of large lymphoid cells and total destruction of the normal lymph node architecture ( Fig. 1 ). Among the 60 cases, 38 (63%) were immunohistochemically positive and 22 (37%) were negative for TNF-a. Further, 31 cases (52%) were positive and 29 (48%) were negative for TNFR1, and 49 (82%) were positive and 11 (18%) were negative for TNFR2. Representative photomicrographs of the staining patterns are shown in Figures 2A-F. The tumor cells in positive cases showed cytoplasmic staining for TNFa, TNFR1, and TNFR2. In all cases, the lymphoid cells were positive for CD20 and negative for CD3. The CD5 positivity rate was 2% (1/60 cases). In addition, 19 (32%) and 41 (68%) cases possessed the GCB and non-GCB phenotypes, respectively. All specimens were confirmed to be negative for EBV-encoded RNA by in situ hybridization.
Association of TNFR1 or TNFR2 Expression With the Patients' Clinical and Pathologic Features
There was no significant difference in age, sex, clinical stage, IPI category, CD5 positivity, and immunophenotypical subdivision between the TNFR1-negative and TNFR1-positive patients or between the TNFR2-positive and TNFR2-negative patients. TNFR1 (P < 0.0001) and TNFR2 (P = 0.0060) expressions correlated significantly with TNF-a expression. There was a significant difference in prognosis between patients with positive and negative TNFR1 expression (P = 0.0004) but not between patients with positive and negative TNFR2 expression (P = 0.1592) ( Tables 2, 3 ).
TNFR1 Expression and Prognosis of Patients With DLBCL, NOS
The Kaplan-Meier survival curves for the OS rates relative to TNFR1 expression showed that the TNFR1positive patients had a significantly poorer OS rate (P = 0.0006; log rank test) than the TNFR1-negative patients (Fig. 3A) . The 2-year OS rate for the TNFR1positive and TNFR1-negative patients was 55% and 89%, respectively, and the 5-year OS rate for the TNFR1positive and TNFR1-negative patients was 37% and 89%, respectively. The TNFR1-positive patients tended to have a poorer PFS than the TNFR1-negative patients, although the difference between the 2 groups was not significant (Fig. 3B ).
TNFR2 Expression and Prognosis of Patients With DLBCL, NOS
The Kaplan-Meier survival curves for the OS rates relative to TNFR2 expression showed that the TNFR2positive patients tended to have a poorer OS than the TNFR2-negative patients, although the difference between the 2 groups was not significant (Fig. 4A) . No difference in PFS was observed between the 2 groups ( Fig. 4B ).
Univariate Analyses of Prognostic Factors
Univariate Cox proportional hazards regression analysis showed that TNF-a expression, TNFR1 expression, clinical stage, and IPI category were significant prognostic factors for OS, whereas TNFR2 expression, age, sex, CD5 expression, and immunophenotypical subdivision were not significant prognostic factors for OS (Table 4) . Thus, TNF-a expression and TNFR1 expression were shown to be significant and useful prognostic factors for poor OS. In contrast, TNF-a expression, clinical stage, and IPI category were significant prognostic factors for PFS, whereas TNFR1 expression, TNFR2 expression, age, sex, CD5 expression, and immunophenotypical subdivision were not significant prognostic factors for PFS ( Table 5 ).
Multivariate Analyses of TNFR1 Expression and IPI Category as Prognostic Factors for OS
Multivariate Cox regression analysis indicated that TNFR1 expression and IPI category were significant prognostic factors for OS and were independent of each other ( Table 6 ).
Association Between TNF-a and TNFR1 Expression
The TNF-a-positive cases were more strongly correlated with poorer OS and PFS than the TNF-a-negative cases (P = 0.0019; log rank test) ( Fig. 5A ).
When the TNF-a-negative cases were divided into 2 subtypes on the basis of TNFR1 expression, the Kaplan-Meier survival curves for the OS and PFS rates relative to TNFR1 expression showed no significant difference between the TNFR1-positive and TNFR1-negative subtypes. In contrast, among the TNF-a-positive cases, the Kaplan-Meier survival curves for the OS rates relative to TNFR1 expression revealed that the TNFR1positive patients had a significantly poorer OS (P = 0.0191; log rank test) than the TNFR1-negative patients (Fig. 5B) . No difference in PFS was observed between the 2 groups.
Prognosis of Patients With the TNF-a-positive and TNFR1-positive Subtype of DLBCL, NOS
The Kaplan-Meier survival curves for the OS rates showed that the patients with the TNF-a-positive and TNFR1-positive subtype (n = 27; 45%) had a significantly poorer OS (P < 0.0001; log rank test) than those with the remaining subtypes (Fig. 6A) . The 2-year OS rate for the patients with the TNF-a-positive and TNFR1-positive subtype was 49% and that for the patients with the remaining subtypes was 90%. The 5-year OS rates for the same patient groups were 31% and 90%, respectively. The Kaplan-Meier survival curves for the PFS rates showed that the patients with the TNF-a-positive and TNFR1-positive subtype had a significantly poorer PFS (P = 0.0050; log rank test) than those with the remaining subtypes (Fig. 6B) . The 2-year PFS rate for the patients with the TNF-a-positive and TNFR1-positive subtype was 37% and that for the patients with the remaining subtypes was 74%. The 5-year PFS rates for the same patient groups were 33% and 56%, respectively.
Univariate and Multivariate Analyses of the TNF-a-positive and TNFR1-positive Subtype of DLBCL, NOS Univariate Cox proportional hazards regression analysis showed that the TNF-a-positive and TNFR1positive subtype was a significant prognostic factor for OS and PFS (Table 7) . Multivariate Cox regression analysis indicated that expression of both TNF-a and TNFR1 in tumor cells and the IPI category were significant prognostic factors for OS and PFS and that these factors were independent of each other.
DISCUSSION
We have shown a direct correlation between TNFR1 expression in DLBCL, NOS cells and poor prognosis in patients with DLBCL, NOS, indicating that TNFR1 expression in DLBCL, NOS cells plays an important role in tumor progression. In addition, we clearly identified the TNF-a-positive and TNFR1-positive subtype of DLBCL, NOS to be correlated with poor prognosis. TNF-a is a key cytokine involved in inflammation, immunity, cellular homeostasis, and tumor progression, as well as in proliferation, angiogenesis, invasion, and metastasis. 13, 14 TNF-a is known to act as an autocrine growth factor in normal B cells, suggesting a similar potential role for this cytokine in malignant B cells. 15 Indeed, TNF-a can promote the growth of cells derived from hairy cell leukemia and chronic lymphocytic B-cell leukemia. 16, 17 TNFR1 is universally expressed on many cells and plays a broader role in NF-kB activation compared with TNFR2. 8 Although the TNF-a signal transduction pathway is complex and not completely understood, the proinflammatory effects of TNF-a are attributable to its ability to activate NF-kB. Inhibition of the nuclear translocation of NF-kB specifically blocks TNF-a-induced cell proliferation. 18 The function of TNF-a, which is involved in all stages of tumorigenesis, is deeply related to the activation of NF-kB. NF-kB is critical for TNF-ainduced tumor promotion. 19 TNF-a has been shown to promote tumor cell survival through the induction of genes that encode NF-kB-dependent antiapoptotic molecules. 20 NF-kB can also promote the growth and survival of lymphoma cells, while contributing to resistance against standard antilymphoma therapies. 21 Both TNFR1 and TNFR2 also exist in a soluble form (sTNFRs), and these sTNFRs can be detected in normal serum and urine, 22, 23 although their physiological roles are not completely understood. Elevated sTNFR1 or sTNFR2 levels have been observed in patients with cancer, 22 and patients with non-Hodgkin lymphoma were found to have significantly higher sTNFR1 and sTNFR2 levels than healthy controls. 24 Elevated sTNFR1 levels have also been associated with shorter PFS and OS. 25 However, the biological roles and implications of elevated circulating sTNFR levels in patients with lymphoma still remain uncertain.
Excessive amounts of sTNFRs can potentially originate from the tumor cells themselves or can be produced by reactive lymphocytes and/or macrophages in response to the presence of the tumor, reflecting an abnormal immune response against the tumor. Moreover, in vitro evidence suggests that tumor cells may have a greater tendency to shed soluble cytokine receptor forms because of the enhanced cleavage of cell surface components compared with nonmalignant cells. 26 Increased serum TNF-a levels may induce the shedding of TNFR1 and TNFR2 from cell membranes. 27 However, the origin and accurate mechanism underlying these high sTNFR levels have not been elucidated. Therefore, serum sTNFR levels present many confounding aspects, and previous reports have not eliminated the possibility that elevated sTNFR levels may reflect an active immune response against malignant cells, which could be a sign of a chronic inflammatory process that is not controlled by the host. Therefore, the relationship between elevated serum sTNFR levels and pathogenesis of lymphoma remains unclear.
To the best of our knowledge, this study presents the first immunohistochemical analysis of TNFR1 and TNFR2 expression in DLBCL, NOS cells to examine the relationship between their expression in tumor cells and the prognosis of patients with DLBCL, NOS. In the present study, the TNFR1-positive type of DLBCL, NOS was significantly correlated with a poorer OS and tended to have a poorer PFS than the TNFR1-negative type, and by Cox regression analysis, TNFR1 expression was found to be a significant prognostic factor for OS and was also shown to be independent of the IPI. These findings suggest that TNFR1positive DLBCL, NOS constitutes a unique, clinically aggressive type of DLBCL, NOS, and the predictive prognostic value of IPI may be more significantly improved by the addition of TNFR1 expression. Previously, we reported that the TNF-a-positive type of DLBCL, NOS was correlated with a poorer prognosis than the TNF-a-negative type and that TNF-a expression in tumor cells was a significant prognostic factor, independent of the IPI. 7 The result concerning the TNF-a in this study was consistent with the previously described results. In addition, we revealed the importance of TNFR1 expression as a prognostic factor for patients with DLBCL, NOS in the present study. Therefore, we focused on TNFR1 expression in the TNF-a-positive cases and found that the TNF-a-positive cases were divided into 2 subtypes, TNFR1-positive and TNFR1-negative, and that the TNF-a-positive and TNFR1-positive subtype was correlated with a poorer OS compared with the TNF-a-positive but TNFR1-negative subtype. By Cox regression analysis, the TNF-a-positive and TNFR1positive subtype was shown to be an IPI-independent prognostic factor. The addition of TNFR1 expression to TNF-a expression led to poorer prognosis, suggesting that the tumor cell proliferation by TNF-a occurs by means of TNFR1 through an autocrine mechanism. Combined TNF-a and TNFR1 expression, along with the IPI category, appears to provide an increased amount of prognostic information. Determination of the exact prognosis is important to facilitate the selection of an appropriate therapeutic strategy such as bone marrow transplantation. TNF-a-targeting biological agents may be somewhat effective for TNF-a-positive and TNFR1-positive patients. 28 In conclusion, this study shows that the TNF-apositive and TNFR1-positive subtype of DLBCL, NOS is correlated with poor prognosis. In addition to the IPI, the prognosis of patients can be more accurately identified by evaluating the expression of both TNF-a and TNFR1.
